{"id":890313,"date":"2025-09-29T11:25:34","date_gmt":"2025-09-29T15:25:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/"},"modified":"2025-09-29T11:25:34","modified_gmt":"2025-09-29T15:25:34","slug":"autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/","title":{"rendered":"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0"},"content":{"rendered":"
\n

\n GLP study marks a key milestone in Autonomix’s path to achieve regulatory approvals<\/em>\n <\/p>\n

\n Company remains on track to submit Investigational Device Exemption (\u201cIDE\u201d), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application<\/em>
\n \n <\/p>\n

\n THE WOODLANDS, TX, Sept. 29, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n Autonomix Medical, Inc.<\/a>\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a Good Laboratory Practice (GLP) preclinical study required by the FDA at CBSET, a state-of-the-art pre-clinical translational research institute, for its Sensing and RF Ablation System as a treatment for pancreatic cancer pain.<\/p>\n

This GLP study is a set of quality standards that Autonomix is following to ensure the reliability and integrity of its devices in order to meet regulatory requirements for submitting data to the FDA for IDE clinical trials and product approval.\u00a0<\/p>\n

\u201cThe initiation of this study marks a critical milestone in our regulatory pathway towards potential approval. I am incredibly pleased with the progress made to date and with the continued solid execution of our plan. We remain on track to file our IDE and, if approved, commence clinical studies next year,\u201d commented Brad Hauser, CEO of Autonomix.<\/p>\n

Autonomix\u2019s first-in-class technology constitutes a platform with the potential to address dozens of indications in multiple high-need therapeutic areas, including cardiology and resistant hypertension or high blood pressure, interventional pain management, pulmonary and gastrointestinal disorders, and more. For more information about the Company\u2019s technology, please visit autonomix.com<\/a>.<\/p>\n

\n About CBSET<\/strong>\n <\/p>\n

CBSET is a state-of-the-art translational research institute located in the greater Boston area of MA. Its mission is to advance biomedical research, through innovative, high-quality services. CBSET combines top-tier research with operational expertise. Since its inception, CBSET has continued to develop technical and scientific acumen through collaborative projects in the medical device, pharmaceutical and academic communities. CBSET\u2019s 40,000 square foot, GLP-compliant, AAALAC- accredited facility includes vivaria, procedure rooms, catheterization \/ imaging labs, surgical and necropsy suites, histopathology, SEM, and a range of other technologies.<\/p>\n

\n About Autonomix Medical, Inc.<\/strong>\n <\/p>\n

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company\u2019s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.<\/p>\n

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.<\/p>\n

For more information, visit autonomix.com<\/a> and connect with the Company on X<\/a>, LinkedIn<\/a>, Instagram<\/a> and Facebook<\/a>. <\/p>\n

Forward Looking Statements<\/strong><\/p>\n

Some of the statements in this release are \u201cforward-looking statements,\u201d which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the submission of its IDE and, if approved, the timing of the commencement of clinical studies. Such forward-looking statements can be identified by the use of words such as \u201cshould,\u201d \u201cmight,\u201d \u201cmay,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201cexpects,\u201d \u201cplans,\u201d and \u201cproposes.\u201d<\/p>\n

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading \u201cRisk Factors\u201d and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.<\/p>\n

\n Investor and Media Contact<\/strong>\n <\/p>\n

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GLP study marks a key milestone in Autonomix’s path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (\u201cIDE\u201d), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a Good Laboratory Practice (GLP) preclinical study required by the FDA at CBSET, a state-of-the-art pre-clinical translational research institute, for its Sensing and RF Ablation System as a treatment for pancreatic cancer pain. This GLP study is a set of quality standards that Autonomix is following to ensure … <\/p>\n

Continue reading “Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0“<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-890313","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAutonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GLP study marks a key milestone in Autonomix’s path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (\u201cIDE\u201d), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a Good Laboratory Practice (GLP) preclinical study required by the FDA at CBSET, a state-of-the-art pre-clinical translational research institute, for its Sensing and RF Ablation System as a treatment for pancreatic cancer pain. This GLP study is a set of quality standards that Autonomix is following to ensure … Continue reading "Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T15:25:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0\",\"datePublished\":\"2025-09-29T15:25:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/\"},\"wordCount\":727,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/\",\"name\":\"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==\",\"datePublished\":\"2025-09-29T15:25:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/","og_locale":"en_US","og_type":"article","og_title":"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0 - Market Newsdesk","og_description":"GLP study marks a key milestone in Autonomix’s path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (\u201cIDE\u201d), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a Good Laboratory Practice (GLP) preclinical study required by the FDA at CBSET, a state-of-the-art pre-clinical translational research institute, for its Sensing and RF Ablation System as a treatment for pancreatic cancer pain. This GLP study is a set of quality standards that Autonomix is following to ensure … Continue reading \"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-29T15:25:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0","datePublished":"2025-09-29T15:25:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/"},"wordCount":727,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/","name":"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==","datePublished":"2025-09-29T15:25:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjM5NCM3MTY4NjgxIzUwMDExOTk5Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-inc-initiates-good-laboratory-practice-glp-study-for-sensing-and-rf-ablation-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=890313"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=890313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=890313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=890313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}